MS Clinical Care Connection |
Co-Morbidities Significantly Impact MS |
Recent research shows that co–existing medical and psychiatric conditions have a significant impact on people with MS.
Co–morbidities can:
• Delay the MS diagnosis
• Delay treatment initiation
• Reduce treatment adherence
• Reduce quality of life
• Hasten disability progression
• Increase the risk of hospitalizations
• Shorten the lifespan
The Society’s Wellness Discussion Guide can help facilitate discussion and shared decision-making between people with MS and their healthcare providers about strategies to enhance wellness, address MS symptoms and moderate co-morbidities. The guide summarizes key findings, provides links to comprehensive, peer-reviewed information, highlights key points for patient-provider discussion, and offers the person with MS the opportunity to track questions, goals and progress.
|
|
|
Updated Disease-Modifying Therapies Paper |
The Use of Disease–Modfying Therapies in Multiple Sclerosis: Principles and Current Evidence has been updated to include the newest FDA approved therapies.
The evidence-based paper, developed and endorsed by the nine-member MS Coalition, and endorsed by Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), serves as an education and advocacy tool for people with MS and their healthcare providers. The purpose of the paper is to promote the importance of early and ongoing treatment and full access to all of the disease-modify therapies. There is also a Summary paper available for people living with MS.
|
|
|
|
The National MS Society supports MS healthcare professionals through professional publications, tools and materials, as well as resources to share with patients and their families. Our information and resources are designed to help people affected by MS live their best lives — in partnership with all of the members of the MS comprehensive healthcare team. |